113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax?) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC)

R.Amato; M.Karediy; A.Cao; M.Khan; S.Naylor; M.McDonald; R.Harrop; W.Shingler; P.Chikoti; N.Drury

首页> 外文期刊>European Journal of Cancer Supplements >113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax?) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC)

【24h】

113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax?) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC)

机译：一项113 POSTER II期临床试验，评估了进行性激素难治性前列腺癌（HRPC）患者（pts）中单独MVA5T4（Trovax？）与MVA5T4加粒细胞巨噬细胞集落刺激因子（GM-CSF）的活性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第12期|共1页
作者
R.Amato; M.Karediy; A.Cao; M.Khan; S.Naylor; M.McDonald; R.Harrop; W.Shingler; P.Chikoti; N.Drury;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). [J] . David H Lawson, Sandra Lee, Fengmin Zhao, Journal of Clinical Oncology . 2015,第34期

机译：无局部证据的患者在完全手术切除后无病征兆晚期和/或IV期黑色素瘤：东部合作肿瘤小组-美国放射学院影像网络癌症研究小组（E4697）的试验。
2. 4010 POSTER Satraplatin increases progression-free survival (PFS) and delays pain progression in hormone refractory prostate cancer (HRPC): Results of SPARC, an international phase III trial with 950 patients [J] . C.Sternberg, O.Sartor, D.Petrylak, European Journal of Cancer Supplements . 2007,第4期

机译：4010 POSTER Satraplatin可提高激素难治性前列腺癌（HRPC）的无进展生存期（PFS）并延迟疼痛进展：SPARC的一项国际性III期试验，涉及950名患者
3. 385 A phase II trial to assess the efficacy and safety of gefitinib (Iressa?) in patients with metastatic hormone refractory prostate cancer (HRPC) who progressed on treatment with a luteinising hormone releasing hormone analogue (or post orchiectomy) plus an antiandrogen [J] . G.Curigliano, O.De Cobelli, M.T.Sandri, European Journal of Cancer Supplements . 2004,第8期

机译：385一项II期临床试验，评估吉非替尼（Iressa？）在使用黄体激素释放激素类似物（或睾丸切除术后）加抗雄激素治疗的转移性激素难治性前列腺癌（HRPC）患者中的疗效和安全性
4. Randomized Placebo-Controlled Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E4697) [O] . David H. Lawson, Sandra Lee, Fengmin Zhao, -1

机译：在完全手术切除局部无疾病证据的患者中酵母衍生的粒细胞-巨噬细胞集落刺激因子（GM-CSF）对肽疫苗对GM-CSF加肽疫苗对安慰剂的随机安慰剂对照III期试验晚期和/或IV期黑色素瘤：东部合作肿瘤小组的一项试验-美国放射线影像学学院癌症研究小组（E4697）
5. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer [O] . JA OShaughnessy, A Tolcher, D Riseberg, 1996

机译：前瞻性，随机试验5氟尿嘧啶，白细胞素，多柔比星和环磷酰胺化学疗法与白细胞介素-3 /粒细胞 - 巨噬细胞群刺激因子（GM-CSF）融合蛋白（PIXY321）与先进乳房患者的GM-CSF相结合癌症
6. Phase I/II Trial of 13-Cis Retinoic Acid, Alpha Interferon, Taxotere, and Estramustine (R.I.T.E.) for the Treatment of Hormone Refractory Prostate Cancer [R] . DiPaola, R. S. , Weiss, R. , Shih, W. J. 2006

机译：用于治疗激素难治性前列腺癌的13-顺式维甲酸，α干扰素，泰索帝和雌莫司汀（R.I.T.E.）的I / II期试验

113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax?) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC)

著录项

相似文献

相关主题

期刊订阅